{"id":"W2600971427","doi":"10.1200/jco.2013.31.15_suppl.8537","title":"Secondary efficacy subanalysis by histology from the phase III BRIGHT study: First-line bendamustine-rituximab (BR) compared with standard R-CHOP/R-CVP for patients with advanced indolent non-Hodgkin lymphoma (NHL) or mantle cell lymphoma (MCL).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Bendamustine; Tolerability; Internal medicine; Rituximab; Clinical endpoint; CHOP; Gastroenterology; Phases of clinical research; Lymphoma; Surgery; Adverse effect; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007154082,0.001289638,0.002551363,0.0005968306,0.00025616,0.0008919473,0.0008260278,0.0008315032,0.005964893],"category_scores_gemma":[0.003400044,0.0003874959,0.004301307,0.0004098012,0.0006036187,0.0006503034,0.0005219053,0.001903923,0.0007049886],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006248013,"about_ca_system_score_gemma":0.0008071686,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003478588,"about_ca_topic_score_gemma":0.0009834029,"domain_scores_codex":[0.9971533,0.002084757,0.0001626232,0.0002200202,0.0001906247,0.0001886164],"domain_scores_gemma":[0.9963728,0.001648276,0.0008865569,0.0003484906,0.0002111029,0.0005327734],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9663615,0.00305608,0.00509232,0.0006896443,0.007650962,0.00003456489,0.00004589762,0.0007414838,0.004496083,0.00007711766,0.001434159,0.01032024],"study_design_scores_gemma":[0.5899971,0.3169303,0.07176807,0.00009308158,0.01073952,0.0001544836,0.00008227121,0.001982762,0.004253102,0.0003965877,0.003561979,0.0000408185],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.98445,0.003968544,0.001178628,0.0003490178,0.0002139056,0.003275626,0.003652957,0.00008734295,0.002823951],"genre_scores_gemma":[0.9874414,0.0008511598,0.001179721,0.0008442098,0.0002760011,0.003070731,0.003437805,0.00004419363,0.002854733],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007154082,"threshold_uncertainty_score":0.03783482,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03227101687520967,"score_gpt":0.3674593381366304,"score_spread":0.3351883212614207,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}